KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Receivables: 2009-2025

Historic Receivables for Acadia Pharmaceuticals (ACAD) over the last 11 years, with Sep 2025 value amounting to $139.4 million.

  • Acadia Pharmaceuticals' Receivables rose 26.34% to $139.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $477.5 million, marking a year-over-year increase of 12.84%. This contributed to the annual value of $104.7 million for FY2024, which is 2.29% up from last year.
  • Acadia Pharmaceuticals' Receivables amounted to $139.4 million in Q3 2025, which was up 16.50% from $119.7 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Receivables registered a high of $139.4 million during Q3 2025, and its lowest value of $51.8 million during Q2 2021.
  • Moreover, its 3-year median value for Receivables was $104.7 million (2024), whereas its average is $104.5 million.
  • In the last 5 years, Acadia Pharmaceuticals' Receivables fell by 8.97% in 2022 and then soared by 68.40% in 2023.
  • Over the past 5 years, Acadia Pharmaceuticals' Receivables (Quarterly) stood at $65.3 million in 2021, then decreased by 3.46% to $63.1 million in 2022, then soared by 62.25% to $102.3 million in 2023, then rose by 2.29% to $104.7 million in 2024, then climbed by 26.34% to $139.4 million in 2025.
  • Its last three reported values are $139.4 million in Q3 2025, $119.7 million for Q2 2025, and $113.7 million during Q1 2025.